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detection of endoleaks
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Objective: Computed tomographic (CT) scan represents the criterion standard for surveillance of endoleaks after
endoluminal repair of abdominal aortic aneurysms (erAAAs). Given need for surveillance, risks, and expense of CT scan,
the accuracy of color-flow duplex (CFD) scan after erAAA was determined.
Methods: During a 43-month period, patients enrolled in phase II and III of the AneuRx Multicenter Clinical Trial
at our institution underwent CFD scan 1 month after erAAA. Patients with CFD scan results that were positive for
endoleak underwent CT scanning at 3 months after erAAA, and those with CFD scan results that were negative for
endoleak underwent CT scanning at 6 months after erAAA.
Results: Seven of 79 patients (9%) who underwent CFD and CT scanning had the diagnosis of endoleak. All
endoleaks that were diagnosed with CT scan were detected with CFD scan. One patient had positive results for
endoleak with CFD scan at 1 month and then negative results with CT scan at 3 months. Although this may represent
resolution of endoleak, this case was counted as a false-positive result. When compared with CT scan, CFD scan had
a sensitivity of 100%, specificity of 99%, positive predictive value of 88%, negative predictive value of 100%, and
accuracy of 99%.
Conclusion: CFD scan is an accurate test for the detection of endoleak after erAAA. In addition, most endoleaks
diagnosed with CFD scan at 1 month continued to be present at 6 months. This important finding increases the
emphasis on the use of this noninvasive test and may initiate earlier intervention of endoleak. (J Vasc Surg 2002;36:
100-4.)
Infrarenal abdominal aortic aneurysm (AAA) repair
with exclusion with an endoluminal prosthetic graft repre-
sents a newly approved technology for selected patients.
Less defined but well established are complications unique
to endoluminal repair of AAA (erAAA), such as endoleak,
graft migration, and continued aneurysm growth.1-3 Com-
puted tomographic (CT) scan remains the criterion stand-
ard in detection of these occurrences, with primary focus on
the early detection of persistent endoleak. Although safe in
most patients, the use of CT scan as the test for life-long
surveillance is beset with radiation exposure, susceptibility
to contrast allergy, and the risk of contrast nephropathy in
patients with chronic renal failure.4-9
Color-flow duplex scanning (CFD scan) may represent
an alternative to CT scan for surveillance of erAAA. Al-
though CFD scan represents a safe, less-expensive, and
well-tolerated method of diagnosis, measurement, and
monitoring of the size of AAA, reports concerning the
accuracy for the detection of endoleak remain to be assim-
ilated and compared. Given that most early interventions
performed after erAAA are for persistent endoleak, we
examined the use of CFD scan for this means. Herein, we
review our experience and previous reports with CFD scan
for the detection of endoleak.
METHODS
Between June 1997 and July 1999, all erAAAs were
performed with the AneuRx graft (Medtronics AVE,
Sunnyvale, Calif) with prospective phase II and phase III
Food and Drug Administration protocols. Both protocols
were approved by the Institutional Review Board, and
informed consent was obtained from all patients. All pa-
tients underwent erAAA at Memorial Medical Center in
Springfield, Ill, with the direction of vascular surgeons in
the Division of Vascular Surgery at Southern Illinois Uni-
versity, School of Medicine. Patient information was pro-
spectively maintained in a data registry (Access, Microsoft,
Inc, Seattle, Wash). Information regarding the design and
deployment of the AneuRx graft has been previously re-
ported.10
According to the AneuRx phase II and III protocols,
CT scan was routinely obtained at baseline, before dis-
charge after erAAA, 6 months, 12 months, and yearly
thereafter. Contrast-enhanced helical CT scan with 2-mm
slices was performed according to protocol requirements as
previously reported by our institution.11 Briefly, spiral CT
scan was obtained from the origin of the celiac artery to the
bifurcation of the femoral arteries with 3-mm collimation
and 2-mm reconstruction. Strict adherence to a standard-
ized protocol was used and included precontrast imaging
with similar collimation, standard timing of contrast bolus,
and delayed imaging. If no endoleak was detected on the
predischarge CT scan results, then CFD scan was obtained
at the 1-month follow-up examination. If endoleak was
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visualized on the predischarge CT scan results, a repeat CT
scan was obtained at the 2-week follow-up examination. If
an endoleak was absent at 2 weeks, a CFD scan was ob-
tained at 1 month. If endoleak was present at 2 weeks, a CT
scan was obtained at 1 month. If endoleak was detected
with either of these tests at 1 month, a CT scan at the
3-month follow-up examination was obtained. According
to protocol, endoleaks were classified as arising from prox-
imal, distal, or junctional graft attachment sites (types I and
III), from branch vessel flow (Type II), or from undeter-
mined source. No difference was found in the imaging
algorithm for the detection of endoleak between phase II
and phase III AneuRx protocols. All CFD scans were
performed in a fully accredited vascular laboratory (Inter-
societal Commission for the Accreditation of Vascular Lab-
oratories) at Memorial Medical Center (Springfield, Ill) by
registered vascular technologists.
After overnight fasting, examination with CFD scan
was begun with the patient in the supine position with the
head of the bed elevated slightly at 10 degrees. Imaging of
the aorta was performed from the celiac artery to the iliac
bifurcation in the longitudinal and transverse axes. The iliac
and common femoral arteries were scanned in a similar
fashion. Transverse measurements, relative to the vessel,
were made just proximal to the celiac artery, at the level of
the renal arteries, at the maximal aneurysm diameter, and
just proximal to the iliac bifurcation. Measurement of the
proximal, middle, and distal common and external iliac
arteries in the transverse axis was performed. Similarly,
Doppler scan waveforms and velocity measurements were
obtained proximally, within, and distal to the endograft.
Color-flow mode was used to help identify endoleaks with
further focus on determining the origin. With B-mode
ultrasound scan, close attention was given to possible mi-
gration of the graft from the intended location, moving
parts or flaps, compression or twisting of the graft, and the
presence of retroperitoneal fluid. Low frequency transduc-
ers ranging from 2.0 to 3.5 MHz were used with either the
Quantum 2000 scanner (Quantum Medical Systems, Issa-
quah, Wash) or the Philips P800 scanner (Philips, North
American Corp, Itasca, Ill).
Sensitivity, specificity, positive predictive value, nega-
tive predictive value, and accuracy of CFD scan at 1 month
of follow-up study as compared with the criterion standard
of CT scan at 6 months of follow-up study were calculated.
Simultaneous CFD scan and CT scan were not performed
in our patient cohort. Further information about the use of
CFD scan for the identification of endoleaks after erAAA
was obtained with a Medline computer search program.
Journal articles were cross-referenced to obtain more infor-
mation. For those publications with results amendable to
similar analysis, individual and combined contingency ta-
bles were calculated for the use of CFD scan in the detec-
tion of endoleak.
RESULTS
During the study period, 98 patients underwent erAAA
in the phase II and phase III AneuRx graft trial at our
institution (Fig). Of these, 79 patients (78%) had a CFD
scan at the 1-month follow-up examination. Three patients
(3.6%) had to have CT scan at the 1-month follow-up
examination because the CFD scan could not be performed
as a result of the presence of large body habitus or bowel
gas. These patients had negative results for endoleak with
CT scan at 1 month of follow-up study. Of the 76 patients
with a technically acceptable CFD scan at 1 month, seven
(9%) had positive results for endoleak at 6 months with CT
scan. Five patients who had negative results for endoleak at
1 month with CFD scan did not have CT scan at 6 months.
One patient died of congestive heart failure before 6
months, one patient was unable to return, and three pa-
tients had lapses in scheduling. These remaining four pa-
tients had negative results for endoleak at 12 months. Four
patients who had positive results for endoleak with CFD
scan at 1 month did not have a CT scan at 3 months because
of scheduling problems. All of these patients still had pos-
itive results for endoleak at 6 months with CT scan.
Review of the prior CT scans obtained for patients with
CFD scans with positive results for endoleak revealed that
six of the seven patients had endoleak with CT scan at
predischarge and at the 2-week follow-up examination.
Despite correlation with the prior CT scans and the
1-month CFD scan, these patients had a protocol violation
because of scheduling error. One patient had negative
predischarge CT scan results for endoleak and was subse-
quently found to have endoleak with CFD scan.
All persistent endoleaks were classified as type II
(branch vessel flow) with CT scan at 6 months. One patient
had CFD scan positive results for endoleak at 1 month and
then negative results with CT scan at 6 months. Although
this could represent subsequent thrombosis of the endoleak
after the CFD scan, the examination with CFD scan was
classified as a false-positive for purposes of accuracy calcu-
lations. When compared with CT scan at 6 months, CFD
scan had a sensitivity, specificity, positive predictive value,
negative predictive value, and accuracy of 100%, 99%, 88%,
100%, and 99%, respectively. In addition, if the CFD scan
that was designated as a false-positive was changed to a
true-positive (assuming spontaneous thrombosis oc-
curred), then 86% of endoleaks discovered at 1 month
persisted to 6 months with CT scan evaluation. Conversely,
all endoleaks that persisted to 6 months were detected with
CFD scan at 1 month. Other abnormalities, such as en-
dograft migration, compression of the endograft, or retro-
peritoneal fluid, were not identified with CFD scan at 1
month and compared favorably with CT scan at 6 months.
Nine journal articles were found that examined the use
of CFD scan after erAAA.12-20 One article outlined in detail
a CFD scan protocol to identify endoleaks and stated that
“comparable data of poststent color duplex findings and
spiral CT scan indicates that ultrasound can reliably deter-
mine persistent leaks.”13 This article provided no specific
data to support this conclusion and was not used in further
analysis. With the inclusion of the results of our study, 553
patients are reported to have undergone CFD scan and CT
scan after erAAA. One hundred sixteen of these patients
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(21%) had endoleak with CT scan, of which 106 were
corroborated with CFD scan. With the inclusion of our
own data, the combined sensitivity, specificity, positive
predictive value, negative predictive value, and accuracy
were 95%, 97%, 77%, 98%, and 93%, respectively. Table I
lists the pertinent methods used in each study as compared
with this study. Table II shows the sensitivity, specificity,
positive predictive value, negative predictive value, and
accuracy for each study and the combined results.
DISCUSSION
ErAAA has become an accepted alternative to surgery
for selected patients. Successful treatment is presumed to
be dependent on complete exclusion of the aneurysm with-
out the presence of endoleak. Previous series of erAAA have
reported endoleak ranging from 13% to 44%.21-25 The
persistence or subsequent development of perigraft flow
necessitates that patients undergoing erAAA have life-long
surveillance, most intensive in the first year of follow-up.
CT scan has represented the criterion standard to detect
endoleak but is not without risks, given the amount of
follow-up examination needed in the first year, particularly
if an endoleak is present. Radiation exposure, contrast
allergy, expense, inconvenience, and most importantly
nephrotoxicity in patients with chronic renal insufficiency
may represent potential problems that affect a significant
subset of patients suitable for erAAA. Because most early
interventions after erAAA are for further diagnosis and
potential treatment of endoleak, CFD scan may represent
an alternative to CT scan.
Our data, in combination with eight other series, show
CFD scan to be an accurate imaging method for the detec-
tion of endoleak (Table II). With the exclusion of one small
series with only 17 patients and no endoleaks,9 the preva-
lence of endoleaks for different patient cohorts undergoing
CFD scan ranged from 5% to 33%. Unfortunately, three
series reporting the use of CFD scan do not state whether
CT scan was performed during the same time frame. Our
series did not image the graft with CFD scan and CT scan at
the same follow-up period, which represents a flaw in the
calculation of the true accuracy of CFD scan.
One endoleak that was imaged with CFD scan at 1
month was not present at 6 months with CT scan. Al-
though this could represent spontaneous thrombosis, CFD
scan could have been falsely positive and was counted as so.
Zannetti et al19 reported the largest series with an accu-
racy of 89%. These patients underwent CFD and CT
scanning at the same follow-up period.19 Several different
types of grafts, including AneuRx, were used in their study,
as viewed in Table II. Given the similarity in accuracy
between these studies and ours, CFD scan probably has no
distinct advantage with any particular type of graft.
Although CT scan may be the best imaging method for
diagnosis of endoleak, unsatisfactory contrast administra-
tion and artifact from metallic stents may lead to an erro-
neous diagnosis. Three of the six studies showed endoleak
Flow diagram of imaging for endoleak at 1, 3, and 6 months after erAAA with AneuRx graft.
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to be present with CFD scan and not with CT scan in a
small subset of patients. With the consideration that the
results of CFD scan can be extremely dependent on the
experience of the technologist, endoleaks may be more apt
to be diagnosed with CFD scan in certain circumstances (ie,
an optimal examination by an experienced technologist). In
addition, the use of an ultrasound scan contrast agent may
improve the ability of CFD scan in detection of endoleak.
Heilberger et al12 used Levovist (Schering Company, Ber-
lin, Germany) to improve the signal to noise ratio to
identify endoleak. Lastly, CFD scan may be a more dynamic
study in that the direction of flow and source of the
endoleak may be more readily determined.10 We were
unable to reliably determine the origin of endoleak with
CFD scan although its location in relation to the graft was
more easily defined.
Table I. Study methods examining of CFD for detection of endoleaks after erAAA
Authors Graft type
No. of
patients
Percent of
endoleaks CFD follow-up
CT scan
follow-up
Imaging during
same time frame
Heilberger et al12 (1997) Chuter device* 102 26 3-6 months 3-6 months Yes
Stentor†
EGS‡
Berdejo et al14 (1998) EGS‡ 33 33 3-5 days 3-5 days Not stated
3-6 months 3-6 months
Kronzon et al15 (1998) EGS‡ 17 0 2-30 days 2-5 days Not stated
Sato et al16 (1998) EGS‡ 74 Not stated Not stated  Not stated  Not stated
Thompson et al17 (1998) EGS‡ 20 20 3 and 6 months 3 and 6 months Yes
Stentor†
Aortouniiliac
graft§
Fletcher et al18 (2000) EVT 36 8 Not stated Not stated Yes
Zannetti et al19 (2000) AneuRx¶ 103 5 1, 6, 12 months 1, 6, 12 months Yes
Excluder**
Talent††
D’ Audiffret et al20 (2001) Vanguard‡‡ 89 29 1, 3, 6, 12, 18,
24 months
1, 3, 6, 12, 18,
24 months
Yes
Stenford§§
EGS‡
Stentor†
AneuRx¶
Talent††
This report AneuRx¶ 79 11 1 month 3 or 6 months No
*Chuter device  multiple industry sponsors.13
†Stentor graft (MinTec, Freeport, Grand Bahama).
‡EGS aortic endograft (Endovascular Technologies, Menlo Park, Calif).
§Aortouniliac graft  multiple industry sponsors.17
EVT stent graft (Endovascular Technologies, Menlo Park, Calif).
¶AneurRx stent graft (Medtronics, Sunnyvale, Calif).
**Excluder stent graft (W. L. Gore, Inc., Flagstaff, Ariz).
††Talent stent graft (World Medical, Inc., Sunrise, Fl).
‡‡Vanguard stent graft (Boston Scientific Corp., Natick, Mass).
§§Stenford Cardiovascular Endoprosthesis (Stenford Valendons, Suresnes, France).
 Protocol for North American Endovascular Technologies endovascular repair for AAA20 states that follow-up for CFD was at 6 weeks, 6 months, and 1 year,
and follow-up for CT was at 6 months and 1 year.
Table II. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for studies examining
use of CFD compared with CT scan for detection of endoleak after erAAA. Numbers represent percent.
Authors Sensitivity Specificity Positive predictive value Negative predictive value Accuracy
Heilberger et al12 95 95 84 99 95
Berdejo et al14 80 91 80 91 88
Kronzon et al15 — 94 0 98 82
Sato et al16 97 74 66 98 82
Thompson et al17 100 100 100 100 100
Fletcher et al18 100 100 100 100 100
Zannetti et al19 92 98 79 99 98
D’ Audiffret et al20 96 94 89 98 89
This report 100 99 88 100 99
Combined 95 97 77 98 93
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From these data, CFD scan and CT scan are not
mutually exclusive tests but rather complimentary. One
important finding from this study was that all endoleaks
present at 6 months with CT scan were present at 1 month
with CFD scan. Given this fact, early use of CFD scan may
allow for immediate intervention to delineate and treat
endoleak. Nevertheless, the importance of a baseline CT
scan after erAAA should not be underestimated for pur-
poses of comparison with longer-term follow-up periods,
particularly in regards to monitoring for graft migration
and changes in aneurysm size. Therefore, we recommend,
as a first imaging test, a baseline CT scan after erAAA at 1
month. If the results are negative for endoleak, then a CT
scan at 6 months and yearly thereafter is recommended. If
the 1-month CT scan had positive results for endoleak,
then CFD scan should be performed at 3 months because
some endoleaks will spontaneously thrombose. The results
of CFD scan should guide the clinician as to whether
further intervention is needed if endoleak is present. We
perform arteriography for further delineation and potential
endovascular treatment if endoleak persists at 3 months
after erAAA. The role of CFD scan remains less clear for
long-term follow-up study. Important questions about
graft migration and subtle changes in aneurysm size may be
more difficult to discern with CFD scan, particularly in the
absence of endoleak.
To improve quality assurance, emphasis should be
placed on the establishment of standardized protocols for
the method of CT and CFD scans in the detection of
endoleak. For establishment of CT scan as the criterion
standard, strict adherence to general principles, such as
2-mm collimation and the use of delayed imaging, are
paramount. For CFD scan to provide reliable information,
a systematic interrogation with B-mode imaging and wave-
form analysis of the aortoiliac arteries and stent graft is
necessary. With proper training and adequate experience,
CFD scan can be an accurate test for the detection of
endoleak after erAAA. CFD scan and CT scan remain
complimentary imaging methods and may be effectively
incorporated into a surveillance program.
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